- Home
- ONFO vs APVO Comparison
ONFO vs APVO Comparison
Compare ONFO & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONFO
- APVO
- Stock Information
- Founded
- ONFO 2018
- APVO 2016
- Country
- ONFO United States
- APVO United States
- Employees
- ONFO N/A
- APVO N/A
- Industry
- ONFO Computer Software: Programming Data Processing
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- ONFO Technology
- APVO Health Care
- Exchange
- ONFO Nasdaq
- APVO Nasdaq
- Market Cap
- ONFO 6.7M
- APVO 5.4M
- IPO Year
- ONFO 2022
- APVO N/A
- Fundamental
- Price
- ONFO $1.31
- APVO $3.47
- Analyst Decision
- ONFO
- APVO Strong Buy
- Analyst Count
- ONFO 0
- APVO 1
- Target Price
- ONFO N/A
- APVO $296.00
- AVG Volume (30 Days)
- ONFO 18.5K
- APVO 44.0K
- Earning Date
- ONFO 11-15-2024
- APVO 03-04-2025
- Dividend Yield
- ONFO N/A
- APVO N/A
- EPS Growth
- ONFO N/A
- APVO N/A
- EPS
- ONFO N/A
- APVO N/A
- Revenue
- ONFO $6,590,171.00
- APVO N/A
- Revenue This Year
- ONFO $133.59
- APVO N/A
- Revenue Next Year
- ONFO N/A
- APVO N/A
- P/E Ratio
- ONFO N/A
- APVO N/A
- Revenue Growth
- ONFO 29.25
- APVO N/A
- 52 Week Low
- ONFO $0.39
- APVO $3.01
- 52 Week High
- ONFO $1.88
- APVO $399.60
- Technical
- Relative Strength Index (RSI)
- ONFO 48.15
- APVO 33.42
- Support Level
- ONFO $1.35
- APVO $3.20
- Resistance Level
- ONFO $1.48
- APVO $3.65
- Average True Range (ATR)
- ONFO 0.11
- APVO 0.34
- MACD
- ONFO 0.01
- APVO 0.01
- Stochastic Oscillator
- ONFO 28.95
- APVO 31.51
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.